We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Deep Learning Model Accurately Counts Cell Types in Whole Slide Images

By LabMedica International staff writers
Posted on 19 Apr 2023
Print article
Image: A deep learning framework estimating cell types in a whole slide digital pathology image (Photo courtesy of University of Eastern Finland)
Image: A deep learning framework estimating cell types in a whole slide digital pathology image (Photo courtesy of University of Eastern Finland)

Improved methods for counting cell types in pathology images using deep learning approaches are much needed. Current techniques based on segmentation and regression face challenges such as the necessity for precise pixel-level annotations, difficulties in handling overlapping nuclei or obscured regions, and insufficient information on individual cell type locations. Moreover, probabilistic models tend to yield uncertain predictions and can lead to overconfident predictions. Researchers have now developed an advanced deep learning model to predict and count various cell types in the tumor microenvironment, which is expected to enhance the accuracy and efficiency of cancer diagnostics and treatment planning.

Identifying the different cell types in the tumor microenvironment can offer valuable insights into the tumor's histology and underlying biology. Precise and reliable cell type counting is also crucial for research and clinical applications. In addition, cell counts can be used to study the distribution of different cell types in the tumor microenvironment and its correlation with patient outcomes. In clinical settings, cell counts can help monitor therapy response and track disease progression. Researchers from the University of Eastern Finland (Kuopio, Finland) have proposed a new evidential multi-task deep learning approach, called CT-EMT, to overcome the limitations of current methods for cell type counting in whole slide tumor images. This approach formulates cell type density estimation and cell type counting as regression tasks, and nuclei segmentation as a pixel-level classification task.

The proposed cell type segmentation and counting approach has outperformed state-of-the-art HoVer-Net and StarDist models, with relative improvements of 21% and 12% in terms of mean panoptic quality. The developed model can deliver persuasive interpretations of diverse cell types and can be applied to various computational pathology tasks, such as tumor grading, prognosis, and treatment planning. This work will pave the way for the creation of more accurate and robust digital pathology tools that can support pathologists and clinicians in diagnosing and treating cancer patients.

“The UEF Cancer AI research team aims to explore the potential of using deep learning technology in cancer and health data analysis,” said senior researcher Hamid Behravan of the University of Eastern Finland. “Our study will involve the development and evaluation of cutting-edge deep learning algorithms for analyzing cancer and various types of health-related data, including medical images, genomic data, and electronic health records. We believe that this approach has the potential to significantly improve the accuracy and efficiency of breast cancer diagnosis and treatment planning, as well as to facilitate the discovery of new insights and patterns in cancer data. We hope that our research will contribute to the advancement of precision medicine and the development of more effective and personalized approaches to breast cancer prevention and prognosis.”

Related Links:
University of Eastern Finland

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Cortisol/Cortisone Saliva Controls
MassCheck Chromsystems Saliva Controls
New
Liquid Based Cytology Production Machine
LBP-4032

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.